Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

OCS vs ISRG vs HOLX vs SYK vs ABT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OCS
Oculis Holding AG

Biotechnology

HealthcareNASDAQ • CH
Market Cap$1.89B
5Y Perf.+236.5%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$159.85B
5Y Perf.+60.3%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+19.9%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$109.33B
5Y Perf.+11.8%
ABT
Abbott Laboratories

Medical - Devices

HealthcareNYSE • US
Market Cap$146.59B
5Y Perf.-27.7%

OCS vs ISRG vs HOLX vs SYK vs ABT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OCS logoOCS
ISRG logoISRG
HOLX logoHOLX
SYK logoSYK
ABT logoABT
IndustryBiotechnologyMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - DevicesMedical - Devices
Market Cap$1.89B$159.85B$16.97B$109.33B$146.59B
Revenue (TTM)$504K$10.58B$4.13B$25.12B$43.84B
Net Income (TTM)$-104M$2.98B$544M$3.25B$13.98B
Gross Margin-28.6%66.3%52.8%63.5%54.0%
Operating Margin-155.4%30.5%17.5%22.4%17.8%
Forward P/E43.3x17.2x19.1x15.4x
Total Debt$1M$303M$2.63B$14.86B$15.28B
Cash & Equiv.$28M$3.37B$1.96B$4.01B$7.62B

OCS vs ISRG vs HOLX vs SYK vs ABTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OCS
ISRG
HOLX
SYK
ABT
StockMay 21May 26Return
Oculis Holding AG (OCS)100336.5+236.5%
Intuitive Surgical,… (ISRG)100160.3+60.3%
Hologic, Inc. (HOLX)100119.9+19.9%
Stryker Corporation (SYK)100111.8+11.8%
Abbott Laboratories (ABT)10072.3-27.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: OCS vs ISRG vs HOLX vs SYK vs ABT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ABT leads in 5 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Oculis Holding AG is the stronger pick specifically for recent price momentum and sentiment. ISRG also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
OCS
Oculis Holding AG
The Momentum Pick

OCS is the #2 pick in this set and the best alternative if momentum is your priority.

  • +74.5% vs ABT's -35.3%
Best for: momentum
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG ranks third and is worth considering specifically for growth exposure and long-term compounding.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs OCS's 236.5%
  • 20.5% revenue growth vs OCS's -49.6%
Best for: growth exposure and long-term compounding
HOLX
Hologic, Inc.
The Defensive Pick

HOLX is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.45, Low D/E 52.0%, current ratio 3.75x
Best for: sleep-well-at-night
SYK
Stryker Corporation
The Lower-Volatility Pick

Among these 5 stocks, SYK doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ABT
Abbott Laboratories
The Income Pick

ABT carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 11 yrs, beta 0.22, yield 2.6%
  • PEG 0.51 vs ISRG's 1.99
  • Beta 0.22, yield 2.6%, current ratio 1.67x
  • Lower P/E (15.4x vs 19.1x), PEG 0.51 vs 1.28
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs OCS's -49.6%
ValueABT logoABTLower P/E (15.4x vs 19.1x), PEG 0.51 vs 1.28
Quality / MarginsABT logoABT31.9% margin vs OCS's -206.5%
Stability / SafetyABT logoABTBeta 0.22 vs ISRG's 1.00
DividendsABT logoABT2.6% yield, 11-year raise streak, vs SYK's 1.2%, (3 stocks pay no dividend)
Momentum (1Y)OCS logoOCS+74.5% vs ABT's -35.3%
Efficiency (ROA)ABT logoABT16.6% ROA vs OCS's -61.8%, ROIC 9.9% vs -106.8%

OCS vs ISRG vs HOLX vs SYK vs ABT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OCSOculis Holding AG

Segment breakdown not available.

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B
ABTAbbott Laboratories
FY 2024
Medical Devices
45.3%$19.0B
Diagnostic Products
22.3%$9.3B
Nutritional Products
20.1%$8.4B
Established Pharmaceutical Products
12.4%$5.2B

OCS vs ISRG vs HOLX vs SYK vs ABT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLABTLAGGINGSYK

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

ABT is the larger business by revenue, generating $43.8B annually — 86990.1x OCS's $504,000. ABT is the more profitable business, keeping 31.9% of every revenue dollar as net income compared to OCS's -206.5%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOCS logoOCSOculis Holding AGISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…ABT logoABTAbbott Laboratori…
RevenueTrailing 12 months$504,000$10.6B$4.1B$25.1B$43.8B
EBITDAEarnings before interest/tax-$78M$3.8B$974M$6.3B$10.9B
Net IncomeAfter-tax profit-$104M$3.0B$544M$3.2B$14.0B
Free Cash FlowCash after capex-$61M$2.8B$1000M$4.3B$6.9B
Gross MarginGross profit ÷ Revenue-28.6%+66.3%+52.8%+63.5%+54.0%
Operating MarginEBIT ÷ Revenue-155.4%+30.5%+17.5%+22.4%+17.8%
Net MarginNet income ÷ Revenue-206.5%+28.2%+13.2%+12.9%+31.9%
FCF MarginFCF ÷ Revenue-121.8%+26.8%+24.2%+17.1%+15.8%
Rev. Growth (YoY)Latest quarter vs prior year+23.0%+2.5%+11.4%+6.9%
EPS Growth (YoY)Latest quarter vs prior year+33.3%+18.8%-9.2%+56.0%0.0%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ABT leads this category, winning 5 of 7 comparable metrics.

At 11.0x trailing earnings, ABT trades at a 81% valuation discount to ISRG's 57.2x P/E. Adjusting for growth (PEG ratio), ABT offers better value at 0.37x vs ISRG's 2.63x — a lower PEG means you pay less per unit of expected earnings growth.

MetricOCS logoOCSOculis Holding AGISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…ABT logoABTAbbott Laboratori…
Market CapShares × price$1.9B$159.8B$17.0B$109.3B$146.6B
Enterprise ValueMkt cap + debt − cash$1.9B$156.8B$17.6B$120.2B$154.2B
Trailing P/EPrice ÷ TTM EPS-12.01x57.19x30.53x33.98x11.03x
Forward P/EPrice ÷ next-FY EPS est.43.35x17.21x19.06x15.40x
PEG RatioP/E ÷ EPS growth rate2.63x2.29x0.37x
EV / EBITDAEnterprise value multiple43.28x17.39x19.76x15.36x
Price / SalesMarket cap ÷ Revenue2144.98x15.88x4.14x4.35x3.49x
Price / BookPrice ÷ Book value/share14.02x9.10x3.43x4.87x3.08x
Price / FCFMarket cap ÷ FCF64.18x18.44x25.53x23.08x
ABT leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ABT leads this category, winning 4 of 9 comparable metrics.

ABT delivers a 27.3% return on equity — every $100 of shareholder capital generates $27 in annual profit, vs $-82 for OCS. OCS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs OCS's 4/9, reflecting strong financial health.

MetricOCS logoOCSOculis Holding AGISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…ABT logoABTAbbott Laboratori…
ROE (TTM)Return on equity-81.7%+16.9%+11.0%+15.0%+27.3%
ROA (TTM)Return on assets-61.8%+14.8%+6.1%+6.9%+16.6%
ROICReturn on invested capital-106.8%+15.0%+9.4%+11.4%+9.9%
ROCEReturn on capital employed-85.4%+16.5%+8.8%+13.0%+10.8%
Piotroski ScoreFundamental quality 0–946767
Debt / EquityFinancial leverage0.02x0.02x0.52x0.66x0.32x
Net DebtTotal debt minus cash-$27M-$3.1B$667M$10.8B$7.7B
Cash & Equiv.Liquid assets$28M$3.4B$2.0B$4.0B$7.6B
Total DebtShort + long-term debt$1M$303M$2.6B$14.9B$15.3B
Interest CoverageEBIT ÷ Interest expense-117.78x8.00x6.72x19.22x
ABT leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

OCS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in OCS five years ago would be worth $33,650 today (with dividends reinvested), compared to $7,982 for ABT. Over the past 12 months, OCS leads with a +74.5% total return vs ABT's -35.3%. The 3-year compound annual growth rate (CAGR) favors OCS at 46.3% vs ABT's -6.3% — a key indicator of consistent wealth creation.

MetricOCS logoOCSOculis Holding AGISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…ABT logoABTAbbott Laboratori…
YTD ReturnYear-to-date+63.2%-19.9%+1.9%-17.8%-31.1%
1-Year ReturnPast 12 months+74.5%-16.4%+35.3%-24.5%-35.3%
3-Year ReturnCumulative with dividends+213.2%+48.5%-8.5%+2.4%-17.8%
5-Year ReturnCumulative with dividends+236.5%+61.7%+16.8%+17.5%-20.2%
10-Year ReturnCumulative with dividends+236.5%+549.2%+124.3%+179.2%+166.6%
CAGR (3Y)Annualised 3-year return+46.3%+14.1%-2.9%+0.8%-6.3%
OCS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — HOLX and ABT each lead in 1 of 2 comparable metrics.

ABT is the less volatile stock with a 0.22 beta — it tends to amplify market swings less than ISRG's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ABT's 60.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOCS logoOCSOculis Holding AGISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…ABT logoABTAbbott Laboratori…
Beta (5Y)Sensitivity to S&P 5000.79x1.00x0.45x0.52x0.22x
52-Week HighHighest price in past year$32.76$603.88$76.04$404.87$139.06
52-Week LowLowest price in past year$16.00$427.84$53.62$284.97$84.08
% of 52W HighCurrent price vs 52-week peak+99.6%+74.5%+100.0%+70.5%+60.6%
RSI (14)Momentum oscillator 0–10069.743.669.126.626.3
Avg Volume (50D)Average daily shares traded364K1.8M10.3M2.1M10.6M
Evenly matched — HOLX and ABT each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — SYK and ABT each lead in 1 of 2 comparable metrics.

Analyst consensus: OCS as "Buy", ISRG as "Buy", HOLX as "Hold", SYK as "Buy", ABT as "Buy". Consensus price targets imply 53.2% upside for OCS (target: $50) vs 3.9% for HOLX (target: $79). For income investors, ABT offers the higher dividend yield at 2.60% vs SYK's 1.18%.

MetricOCS logoOCSOculis Holding AGISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.SYK logoSYKStryker Corporati…ABT logoABTAbbott Laboratori…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuyBuy
Price TargetConsensus 12-month target$50.00$622.60$79.00$389.62$128.71
# AnalystsCovering analysts755425041
Dividend YieldAnnual dividend ÷ price+1.2%+2.6%
Dividend StreakConsecutive years of raises3411
Dividend / ShareAnnual DPS$3.36$2.19
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.4%+4.4%0.0%+0.9%
Evenly matched — SYK and ABT each lead in 1 of 2 comparable metrics.
Key Takeaway

ABT leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). ISRG leads in 1 (Income & Cash Flow). 2 tied.

Best OverallAbbott Laboratories (ABT)Leads 2 of 6 categories
Loading custom metrics...

OCS vs ISRG vs HOLX vs SYK vs ABT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OCS or ISRG or HOLX or SYK or ABT a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Abbott Laboratories (ABT) offers the better valuation at 11. 0x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Oculis Holding AG (OCS) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OCS or ISRG or HOLX or SYK or ABT?

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

0x versus Intuitive Surgical, Inc. at 57. 2x. On forward P/E, Abbott Laboratories is actually cheaper at 15. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 51x versus Intuitive Surgical, Inc. 's 1. 99x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — OCS or ISRG or HOLX or SYK or ABT?

Over the past 5 years, Oculis Holding AG (OCS) delivered a total return of +236.

5%, compared to -20. 2% for Abbott Laboratories (ABT). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus HOLX's +124. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OCS or ISRG or HOLX or SYK or ABT?

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

22β versus Intuitive Surgical, Inc. 's 1. 00β — meaning ISRG is approximately 362% more volatile than ABT relative to the S&P 500. On balance sheet safety, Oculis Holding AG (OCS) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — OCS or ISRG or HOLX or SYK or ABT?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OCS or ISRG or HOLX or SYK or ABT?

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -125. 0% for Oculis Holding AG — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -106. 7% for OCS. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OCS or ISRG or HOLX or SYK or ABT more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 51x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Abbott Laboratories (ABT) trades at 15. 4x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 27. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OCS: 53. 2% to $50. 00.

08

Which pays a better dividend — OCS or ISRG or HOLX or SYK or ABT?

In this comparison, ABT (2.

6% yield), SYK (1. 2% yield) pay a dividend. OCS, ISRG, HOLX do not pay a meaningful dividend and should not be held primarily for income.

09

Is OCS or ISRG or HOLX or SYK or ABT better for a retirement portfolio?

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), 2. 6% yield, +166. 6% 10Y return). Both have compounded well over 10 years (ABT: +166. 6%, OCS: +236. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OCS and ISRG and HOLX and SYK and ABT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OCS is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; HOLX is a mid-cap quality compounder stock; SYK is a mid-cap quality compounder stock; ABT is a mid-cap deep-value stock. SYK, ABT pay a dividend while OCS, ISRG, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OCS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

ABT

Dividend Mega-Cap Quality

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 19%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.